Enanta Pharmaceuticals Stock Forward View - Simple Regression
| ENTA Stock | USD 13.54 -0.20 -1.46% |
Momentum 47
Impartial
Oversold | Overbought |
This section frames Enanta Pharmaceuticals response to recent headlines in a peer context.
The Simple Regression forecasted value of Enanta Pharmaceuticals on the next trading day is expected to be 13.46 with a mean absolute deviation of 0.78 and the sum of the absolute errors of 47.49.Enanta Pharmaceuticals after-hype prediction price | USD 13.54 |
This view helps relate attention signals to forecasting and technical indicators plus earnings context.
Historical Fundamental Analysis of Enanta Pharmaceuticals provides a cross-check on projections for Enanta Pharmaceuticals. The analysis adds historical context for the projection set.Enanta Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Enanta price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Enanta using various technical indicators. When you analyze Enanta charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Enanta Pharmaceuticals Simple Regression Price Forecast For the 10th of March
Given 90 days horizon, the Simple Regression forecasted value of Enanta Pharmaceuticals on the next trading day is expected to be 13.46 with a mean absolute deviation of 0.78 , mean absolute percentage error of 0.98 , and the sum of the absolute errors of 47.49 .Please note that although there have been many attempts to predict Enanta Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Enanta Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Enanta Pharmaceuticals Stock Forecast Pattern
| Backtest Enanta Pharmaceuticals | Enanta Pharmaceuticals Price Prediction | Research Analysis |
Enanta Pharmaceuticals Forecasted Value
This next-day forecast for Enanta Pharmaceuticals uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Enanta Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Enanta Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.0861 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.7786 |
| MAPE | Mean absolute percentage error | 0.055 |
| SAE | Sum of the absolute errors | 47.4927 |
The degree to which Enanta Pharmaceuticals' exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
Enanta Pharmaceuticals After-Hype Price Density Analysis
The after-hype price distribution for Enanta Pharmaceuticals helps investors understand how much of Enanta Pharmaceuticals' predicted return comes from the central scenario versus tail outcomes. Strategies that rely on tail events for Enanta Pharmaceuticals are inherently more speculative.
Next price density |
| Expected price to next headline |
Enanta Pharmaceuticals Estimiated After-Hype Price Volatility
Historical news patterns for Enanta Pharmaceuticals reveal how the market has historically digested different types of information about Enanta Pharmaceuticals' business and market environment. Enanta Pharmaceuticals' after-hype downside and upside margins for the prediction period are 10.14 and 16.94, respectively. The model extrapolates these patterns to estimate likely price boundaries following the next significant.
Current Value
The after-hype framework applied to Enanta Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Enanta Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Enanta Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enanta Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Enanta Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.07 | 3.40 | 0.00 | 0.00 | 0 Events | 4 Events | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
13.54 | 13.54 | 0.00 |
|
Enanta Pharmaceuticals Hype Timeline
Enanta Pharmaceuticals is currently traded for 13.54. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Enanta is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is currently at -0.07%. %. The volatility of related hype on Enanta Pharmaceuticals is about 22666.67%, with the expected price after the next announcement by competition of 13.54. About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Enanta Pharmaceuticals was currently reported as 4.36. The company has Price/Earnings (P/E) ratio of 366.13. Enanta Pharmaceuticals recorded a loss per share of 3.21. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in a few days. Historical Fundamental Analysis of Enanta Pharmaceuticals provides a cross-check on projections for Enanta Pharmaceuticals. The analysis adds historical context for the projection set.Enanta Pharmaceuticals Related Hype Analysis
Peer hype analysis helps investors build a more complete picture of Enanta Pharmaceuticals' competitive environment by quantifying the market's sensitivity to news across all major players in Enanta Pharmaceuticals's sector.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PYXS | Pyxis Oncology | 0.00 | 0 per month | 0.00 | -0.14 | 9.23 | -9.40 | 51.46 | |
| PRLD | Prelude Therapeutics | 0.02 | 6 per month | 6.36 | 0.17 | 16.44 | -12.77 | 36.35 | |
| TNYA | Tenaya Therapeutics | 0.00 | 0 per month | 0.00 | -0.04 | 8.57 | -10.71 | 37.50 | |
| FHTX | Foghorn Therapeutics | 0.00 | 0 per month | 2.85 | 0.12 | 8.60 | -5.16 | 31.12 | |
| NAUT | Nautilus Biotechnology | -0.06 | 8 per month | 4.28 | 0.08 | 9.29 | -7.21 | 39.09 | |
| CRBU | Caribou Biosciences | 0.00 | 0 per month | 4.11 | 0.01 | 7.19 | -5.56 | 20.34 | |
| IMRX | Immuneering Corp | 0.00 | 0 per month | 8.38 | 0.01 | 8.12 | -4.93 | 67.18 | |
| VYGR | Voyager Therapeutics | 0.05 | 7 per month | 2.96 | 0.01 | 5.59 | -5.23 | 19.71 | |
| AVIR | Atea Pharmaceuticals | -0.10 | 6 per month | 1.56 | 0.29 | 8.20 | -2.91 | 17.79 | |
| ASMB | Assembly Biosciences | -0.06 | 12 per month | 0.00 | -0.07 | 5.85 | -7.15 | 19.10 |
Other Forecasting Options for Enanta Pharmaceuticals
The price trajectory of Enanta is the primary concern for any investor assessing it as an opportunity. Enanta Stock price charts are filled with noise that can easily mislead uninformed investment decisions.Enanta Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enanta Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Enanta Pharmaceuticals Market Strength Events
Understanding the market strength of Enanta Pharmaceuticals stock enables investors to assess the security's momentum and responsiveness to broader market forces. These indicators are essential tools for timing trades in Enanta Pharmaceuticals with greater precision.
Enanta Pharmaceuticals Risk Indicators
Reviewing Enanta Pharmaceuticals' basic risk indicators is essential for investors who want to forecast its price and manage their investment risk effectively. This analysis helps identify the amount of risk involved in holding Enanta Pharmaceuticals' and informs decisions about hedging and position.
| Mean Deviation | 2.51 | |||
| Standard Deviation | 3.4 | |||
| Variance | 11.55 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Enanta Pharmaceuticals
Coverage intensity for Enanta Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Enanta Pharmaceuticals Short Properties
Short sentiment tied to Enanta Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 21.3 M | |
| Cash And Short Term Investments | 188.9 M |
More Resources for Enanta Stock Analysis
A structured review of Enanta Pharmaceuticals often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Enanta Pharmaceuticals Stock. Highlighted below are reports that provide context for Enanta Pharmaceuticals Stock:Historical Fundamental Analysis of Enanta Pharmaceuticals provides a cross-check on projections for Enanta Pharmaceuticals. The analysis adds historical context for the projection set. Explore our How to Trade Enanta Stock guide to learn how to trade Enanta Pharmaceuticals effectively.Analysis related to Enanta Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Investors evaluate Enanta Pharmaceuticals using market value and book value, each describing different facets of the business. Intrinsic value is an estimate of what Enanta Pharmaceuticals' fundamentals imply, and it may differ from market and book figures. External forces such as sentiment and macro conditions can shift prices away from fundamental signals. Analytical frameworks help compare those viewpoints.
Value and price for Enanta Pharmaceuticals are related but not identical, and they can diverge across cycles. Evaluation typically reviews profitability, growth, balance sheet strength, industry position, and market signals. By contrast, market price reflects the level where buyers and sellers transact.